Discontinued — last reported Q4 '18
Impairment and restructuring
Operating ExpensesEli Lilly Impairment and restructuring decreased by 77.0% to $84.10M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 75.6%, from $344.00M to $84.10M. Over 3 years (FY 2021 to FY 2025), Impairment and restructuring shows an upward trend with a 15.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ4 2014
Last reportedQ4 2018
How to read this metric
Frequent or large charges may signal poor capital allocation or a need for significant operational turnaround.
Detailed definition
This metric aggregates charges related to the impairment of assets and costs associated with restructuring initiatives,...
Peer comparison
Comparable to 'restructuring charges' or 'special items' reported by most large-cap corporations.
Metric ID:
is_msft_impairment_and_restructuringHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $104.50M | $0.00 | $0.00 | $206.50M | $38.10M | $0.00 | $0.00 | $0.00 | $435.00M | $81.60M | $344.00M | $35.00M | $0.00 | $364.90M | $84.10M |
| QoQ Change | — | — | — | -100.0% | — | — | -81.5% | -100.0% | — | — | — | -81.2% | +321.6% | -89.8% | -100.0% | — | -77.0% |
| YoY Change | — | — | — | — | — | — | -63.5% | — | -100.0% | — | — | — | — | — | -100.0% | +347.2% | -75.6% |
Range$0.00 – $435.00M
Avg YoY Growth+1.6%
Median YoY Growth-75.6%
Impairment and restructuring at Other Companies
Frequently Asked Questions
- What is Eli Lilly's impairment and restructuring?
- Eli Lilly (LLY) reported impairment and restructuring of $84.10M in Q4 2025.
- How has Eli Lilly's impairment and restructuring changed year-over-year?
- Eli Lilly's impairment and restructuring decreased by 75.6% year-over-year, from $344.00M to $84.10M.
- What is the long-term trend for Eli Lilly's impairment and restructuring?
- Over 3 years (2021 to 2025), Eli Lilly's impairment and restructuring has grown at a 15.3% compound annual growth rate (CAGR), from $316.10M to $484.00M.
- What does impairment and restructuring mean?
- One-time costs from restructuring the business or writing down the value of assets.